Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.
1. A method of treating male hypogonadism in a subject in need thereof, the method comprising administering to the subject an oral formulation comprising:
a) testosterone undecanoate;
b) from about 10% to about 90% by weight of a non-sterol solubilizing agent effective for solubilization of the testosterone undecanoate; and
c) from about 2% to about 45% by weight of a mixture of phytosterols or phytosterol esters, wherein the mixture comprises from 40% to 58% by weight of beta-sitosterol or esters thereof; from 20% to 30% by weight of campesterol or esters thereof; from 14% to 22% by weight stigmasterol or esters thereof; from 0 to 6% by weight brassicasterol or esters thereof; from 0 to 5% by weight sitostanol or esters thereof; and from 0 mg/g to 15 mg/g tocopherols;
wherein the phytosterols or phytosterol esters provide increased plasma levels of testosterone following oral administration in comparison to the plasma levels of testosterone produced following oral administration of testosterone undecanoate in a formulation free of phytosterols and phytosterol esters.
2. The method of claim 1 , wherein the oral formulation comprises from 40 to 400 mg of testosterone undecanoate.
3. The method of claim 1 , wherein the oral formulation comprises from 0.1 to 40% by weight testosterone undecanoate.
4. The method of claim 1 , wherein the oral formulation comprises from about 12.5% to about 85% by weight non-sterol solubilizing agent.
5. The method of claim 1 , wherein the non-sterol solubilizing agent is selected from lipids, surfactants, and mixtures thereof.
6. The method of claim 5 , wherein the non-sterol solubilizing agent comprises an ester of a monohydric alcohol with an organic acid.
7. The method of claim 1 , wherein the non-sterol solubilizing agent comprises propylene glycol monolaurate.
8. The method of claim 1 , wherein the non-sterol solubilizing agent comprises polyoxyl 40 hydrogenated castor oil.
9. The method of claim 1 , wherein the oral formulation comprises:
a) from 0.1 to 40% by weight testosterone undecanoate;
b) from about 10% to about 90% by weight the non-sterol solubilizing agent effective for solubilization of the testosterone undecanoate; and
c) from about 2% to about 45% by weight the mixture of phytosterols or phytosterol esters, wherein the mixture comprises from 40% to 58% by weight of beta-sitosterol or esters thereof; from 20% to 30% by weight of campesterol or esters thereof; from 14% to 22% by weight stigmasterol or esters thereof; from 0 to 6% by weight brassicasterol or esters thereof; from 0 to 5% by weight sitostanol or esters thereof; and from 0 mg/g to 15 mg/g tocopherols.
10. The method of claim 9 , wherein the oral formulation comprises from 12.5 to 85% by weight non-sterol solubilizing agent.
11. The method of claim 9 , wherein the non-sterol solubilizing agent comprises propylene glycol monolaurate.
12. The method of claim 9 , wherein the non-sterol solubilizing agent comprises polyoxyl 40 hydrogenated castor oil.
13. The method of claim 9 , wherein the oral formulation is self-emulsifying or self-microemulsifying.
14. The method of claim 9 , wherein the formulation further comprises alpha-tocopherol or alpha-tocopherol acetate.